NEW YORK (GenomeWeb) – Roche said today that the US Food and Drug Administration has provided 510(k) clearance for its Cobas CT/NG assay for use on its Cobas 6800 and 8800 systems. The assay and systems have been cleared to directly detect the DNA of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) in symptomatic and asymptomatic individuals.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.